Accuray Incorporated

LSE:0H8I Stock Report

Market Cap: US$194.1m

Accuray Valuation

Is 0H8I undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0H8I when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0H8I's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0H8I's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0H8I?

Key metric: As 0H8I is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0H8I. This is calculated by dividing 0H8I's market cap by their current revenue.
What is 0H8I's PS Ratio?
PS Ratio0.4x
SalesUS$444.20m
Market CapUS$194.09m

Price to Sales Ratio vs Peers

How does 0H8I's PS Ratio compare to its peers?

The above table shows the PS ratio for 0H8I vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.8x
EKF EKF Diagnostics Holdings
2.2x7.6%UK£116.6m
NIOX NIOX Group
6.4x12.1%UK£255.5m
CREO Creo Medical Group
2.1x-4.9%UK£66.9m
OBI Ondine Biomedical
24.2x66.0%UK£22.9m
0H8I Accuray
0.4x5.5%US$194.1m

Price-To-Sales vs Peers: 0H8I is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (8.8x).

Price to Sales Ratio vs Industry

How does 0H8I's PS Ratio compare vs other companies in the GB Medical Equipment Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.0x6.3%
0H8I Accuray
 0.4x5.5%US$194.09m
SPEC INSPECS Group
0.3x5.5%US$64.51m
YGEN Yourgene Health
0.6xn/aUS$20.48m
0H8I 0.4xIndustry Avg. 3.0xNo. of Companies4PS02.44.87.29.612+
5 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.0x22.5%
0H8I Accuray
 0.4x111.7%US$194.09m
No more companies

Price-To-Sales vs Industry: 0H8I is good value based on its Price-To-Sales Ratio (0.4x) compared to the UK Medical Equipment industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is 0H8I's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0H8I PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: 0H8I is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0H8I forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.99
US$6.13
+207.6%
8.9%US$7.00US$5.50n/a4
Nov ’25US$1.86
US$6.13
+229.3%
8.9%US$7.00US$5.50n/a4
Oct ’25US$1.84
US$6.13
+233.8%
8.9%US$7.00US$5.50n/a4
Sep ’25US$2.14
US$6.13
+186.9%
8.9%US$7.00US$5.50n/a4
Aug ’25US$1.88
US$6.00
+219.3%
11.8%US$7.00US$5.00n/a4
Jul ’25US$1.78
US$6.00
+238.0%
11.8%US$7.00US$5.00n/a4
Jun ’25US$1.73
US$6.00
+247.0%
11.8%US$7.00US$5.00n/a4
May ’25US$2.16
US$8.75
+305.3%
30.6%US$13.00US$6.00n/a4
Apr ’25US$2.49
US$8.75
+251.5%
30.6%US$13.00US$6.00n/a4
Mar ’25US$2.64
US$8.75
+231.3%
30.6%US$13.00US$6.00n/a4
Feb ’25US$2.52
US$8.67
+244.6%
35.7%US$13.00US$6.00n/a3
Jan ’25US$2.83
US$8.50
+200.4%
31.7%US$13.00US$6.00n/a4
Dec ’24US$2.48
US$8.50
+242.9%
31.7%US$13.00US$6.00n/a4
Nov ’24US$2.54
US$8.30
+226.8%
29.4%US$13.00US$6.00US$1.865
Oct ’24US$2.73
US$8.30
+203.9%
29.4%US$13.00US$6.00US$1.845
Sep ’24US$2.97
US$8.30
+179.6%
29.4%US$13.00US$6.00US$2.145
Aug ’24US$4.21
US$8.30
+97.4%
29.4%US$13.00US$6.00US$1.885
Jul ’24US$3.82
US$8.30
+117.6%
29.4%US$13.00US$6.00US$1.785
Jun ’24US$3.50
US$8.30
+137.5%
29.4%US$13.00US$6.00US$1.735
May ’24US$3.25
US$8.30
+155.8%
29.4%US$13.00US$6.00US$2.165
Apr ’24US$2.97
US$8.17
+175.0%
27.5%US$13.00US$6.00US$2.496
Mar ’24US$2.89
US$8.17
+182.3%
27.5%US$13.00US$6.00US$2.646
Feb ’24US$2.46
US$8.17
+232.7%
27.5%US$13.00US$6.00US$2.526
Jan ’24US$2.02
US$8.17
+304.1%
27.5%US$13.00US$6.00US$2.836
Dec ’23US$2.06
US$8.17
+296.8%
27.5%US$13.00US$6.00US$2.486
Nov ’23US$2.02
US$8.33
+312.9%
25.4%US$13.00US$7.00US$2.546

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Guerbet

€330.4m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€26.10

7D

-3.3%

1Y

36.2%

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

0HVB

US$61.32

7D

4.8%

1Y

-17.1%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$409.11

7D

2.1%

1Y

-14.2%